康惠制药控股子公司陕西友帮停产

Core Viewpoint - Kanghui Pharmaceutical (603139.SH) is facing intensified market competition and declining product sales margins, leading to operational adjustments and production halts at its subsidiary Shaanxi Youbang [1][2] Group 1: Company Operations - Shaanxi Youbang, a subsidiary of the company, is experiencing continuous losses due to product adjustments and production challenges, prompting a decision to halt production in workshops 1, 2, and 3 [1] - The halt in production is expected to mitigate further losses and reduce operational costs, aligning with the company's strategic development direction [1] Group 2: Financial Impact - In 2024, Shaanxi Youbang's total assets are projected to account for 16.91% of the company's most recent audited total assets, with its revenue contributing 1.42% to the consolidated revenue [2] - The projected net loss for Shaanxi Youbang in 2024 is estimated at 52.51 million yuan, impacting the company's net profit by 26.78 million yuan, which represents 29.88% of the company's net profit attributable to shareholders [2]